TABLE 2.
Chf1 ubiquitinated peptides | sites | Ubc4+Chf1 | Ubc13/Mms2+Chf1 | Ubc4+Chf2 |
---|---|---|---|---|
M* DK# HGLFSIR | K150 | X | ||
EAISK# IPDQYHPVVFK | K204 | X | X | |
THGCFK# VDDQGNWFLK | K217 | X | ||
VDDQGNWFLK# DVK | K237 | X | X | |
DVK# SSSGTFLNHQR | K240 | X | ||
LSSASTTSK# DYLLHDGDIIQLGMDFR | K260 | X | ||
LK# ANAFNK# EALSR | K300, K306 | X | ||
ANAFNK# EALSR | K306 | X | X | X |
IK# NLQK# LTTGLEQEDCSICLNK | K313, K317 | X
X |
||
NLQK# LTTGLEQEDCSICLNK | K317 | X | ||
| ||||
LIFAGK# QLEDGR | K48 | X | X | |
TLSDYNIQK# ESTLHLVLR | K63 | X | X | |
| ||||
Chf2 ubiquitinated peptides | Sites | Ubc4+Chf2 | Ubc13/Mms2+Chf2 | Ubc4+Chf1 |
| ||||
NIVGGADGSTIVNNSQEMYK# NLR | K211 | X | X | |
K# DKHGLFSIR | K256 | X | ||
KDK# HGLFSIR | K258 | X | X | |
K# AGPGSQLVIGR | K288 | X | X | |
DAISK# IPEQYHPVVFK1 | K310 | X | X | X |
THGCFK# VDSQGNWYIK | K333 | X | ||
VDSQGNWYIK# DVK | K343 | X | X | |
DVK# SSSGTFLNHQR | K346 | X | X | |
LSPASSLSK# DTPLR1 | K366 | X | X | X |
LK# ANSFNK# EALQR | K406, K412 | X
X |
||
ANSFNK# EALQR | K412 | X | X | |
LQNLQK# LTTGIEEEDCSICLCK | K423 | X | ||
Ubiquitin peptides | ||||
| ||||
LIFAGK# QLEDGR | K48 | X | X | |
TLSDYNIQK# ESTLHLVLR | K63 | X | X |
Oxidation (+/− 15.99644 Da)
GlyGly (114.05421 Da)
Same K# detected on peptide with M* and/or longer peptide.